Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (567)	2/14/1999 2:09:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1073

Brian: I said: largely dependent on lowering the margins for human monoclonals That's nonsense, but I hope you know what I was attempting to say..... largely dependent on maintaining margins on human monoclonals while reducing overall cost. Also, one other thing that I forgot to mention.... I have a small private placement in a company that aims to produce antibodies in plants. You'd want to keep an eye on that technology. Monsanto recently moved the first plant-derived protein into human testing, I believe. Rick